• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

Updated Guidance: Management of Hirsutism and Acne in Adolescents

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Describe the clinical work-up of an adolescent girl with hirsutism or acne
2. Discuss the various treatment modalities for adolescents presenting with idiopathic hirsutism or acne

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 1/15/2020 through 1/15/2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

ACOG provides guidance on the diagnosis and management of adolescents with hirsutism and acne, the most common manifestation of hyperandrogenism. While PCOS is the most common cause, making the diagnosis in this age group can be challenging. Furthermore, there are other diagnoses to consider and, while less frequent, may have significant clinical implications.

Diagnosis of Hyperandrogenism

Role of Lab Testing

Hirsutism Treatment – Multimodal Approach

Acne Treatment – Multimodal Approach

Additional Notes

CLINICAL ACTIONS:

Diagnosis of Hyperandrogenism

History

  • Ask about the following
    • Menses: Regular vs irregular
    • Age of thelarche, adrenarche, and menarche
    • Hirsutism: Hair removal and/or shaving
    • Acne: Use of treatments
    • Medications, including possible use of anabolic steroids or testosterone
    • Family history of acne, hirsutism and possible PCOS

Physical exam

  • Key elements include the following
    • BP
    • BMI
    • Derm exam
      • Hyperandrogenism: Acne | Hirsutism
      • Hyperinsulinism: Acanthosis | Skin tags
    • Pelvic exam
      • External examination “may be helpful” to assess presence or absence of clitoromegaly
      • Clitoromegaly definition: Glans >8 mm | Hood length >27.4 mm
      • “Internal vaginal examination is rarely indicated”
  • Hirsutism grading system: Modified Ferriman–Gallwey score (see ‘Learn More – Primary Sources’ for the chart)
    • 9 body areas
    • Scored from 0 to 4 based on extent of hair growth and location
    • Hirsutism: Score >8
  • Acne grading system: No universally agreed upon scoring system or scale
    • Overall severity (related to lesion quality, quantity and location)
      • Mild (only a few lesions)
      • Moderate (higher number of inflammatory papules and pustules on face and trunk)
      • Severe (may include nodules with extensive involvement of face and trunk)
    • Location: Face and/or trunk
    • Quality: Comedonal | Inflammatory (e.g, erythematous papules/nodules) | Mixed
  • Need for Pelvic exam
    • External examination “may be helpful” to assess presence or absence of clitoromegaly
      • Clitoromegaly: Glans >8 mm | Length of the hood >27.4 mm
      • If clitoromegaly present, additional androgen studies warranted
    • “Internal vaginal examination is rarely indicated”
  • Need for pelvic ultrasound
    • Usually not indicated on a routine basis but consider androgen producing tumor if the following are present
      • High laboratory androgen levels | Significant virilization
      • Adrenal ultrasound and CT scan may be used as well, especially if DHEAS is suggestive of adrenal tumor
    • Polycystic ovarian morphology
      • Present in up to 40% of adolescent girls
      • Does not generate a diagnosis of PCOS nor predict future risk

KEY POINTS:

Role of Lab Testing

Regular Menses

  • Free/Total testosterone
    • >200 ng/dL: Consider ovarian tumor
  • DHEAS
    • >700 micrograms/dL: Consider adrenal tumor
  • 17OHP (first thing in the morning)
    • >200 ng/dL: Consider nonclassical congenital adrenal hyperplasia (CAH)

Note: If labwork is normal, consider idiopathic hirsutism and/or acne

Irregular Menses

  • Testosterone, DHEAS and 17OHP (as above) plus
  • LH/FSH
  • Prolactin
  • TSH

Note: If patient meets diagnostic criteria for PCOS (see ‘Related ObG Topics’ below), screen for diabetes and elevated lipids

Hirsutism Treatment – Multimodal Approach

Lifestyle modifications

  • Weight loss for obese patients is effective with multiple other long term benefits aside from addressing hyperandrogenism

Medication

  • Combined hormonal contraceptives (not currently FDA approved for this indication)
    • Effective regardless of route
    • Third-generation progestins (desogestrel, gestodene, and norgestimate): Less androgenic activity vs levonorgestrel
    • Drospirenone (spironolactone derivative): Antiandrogen activity
  • Antiandrogens
    • Spironolactone (approved indication): 50 to 200 mg/day
      • May be used to enhance hormonal contraceptive
    • Less data available on other antiandrogens
  • Other medications
    • Metformin: Used in adolescents with PCOS and insulin resistance

Hair removal

  • Temporary removal
    • Bleaching | Shaving | Waxing Chemical depilatories | Eflornithine cream (approved for facial hirsutism)
  • Permanent removal affecting follicle
    • Electrolysis | Laser

Acne Treatment – Multimodal Approach

  • Consider working with dermatologist for moderate to severe acne and referral for more severe/complex cases (see American Academy of Dermatology guidelines in ‘Learn More – Primary Sources, below)
  • Multiple topical agents are available
    • Benzoyl Peroxide (BP) | Salicylic acid | Antibiotics | Combination antibiotics with BP | Retinoids | Retinoid with BP | Retinoid with antibiotic | Azelaic acid | Sulfone agent
  • Hormonal therapy
    • ACOG considers hormonal therapy (e.g., OCP) “acceptable first-line” therapy in postmenarchal adolescents
    • Additional benefits: Cycle control and contraception
    • May be especially effective for adolescents with flares prior to menses
    • Any OCP with estrogen component should be effective
    • Consider higher generation progestin (see above) if patient not responding to current OCP
  • Spironolactone
    • Start at 25 mg/day and can go up to 100 to 200 mg/day
  • Oral antibiotics
    • Used for moderate to severe with inflammatory lesions following failure of topical therapy
    • Tetracycline | Doxycycline | Minocycline |TMP/SMX | Trimethoprim | Erythromycin| Azithromycin | Amoxicillin | Cephalexin
    • Doxycycline and minocycline are more effective than tetracycline
    • Erythromycin and azithromycin can be effective in treating acne, its use should be limited to those who cannot use the tetracyclines (e.g., pregnancy)
    • Use limited to shortest duration possible
  • Isotretinoin
    • For severe acne
    • Teratogenic in pregnancy
    • Requires compliance with iPLEDGE program (FDA mandated program) to mitigate pregnancy risk (see ‘Primary Sources – Learn More’ below) and use of dual contraception to avoid pregnancy

Additional Notes

  • Hormonal therapy slows growth but does not remove hair | Due to lifespan of terminal hair, counsel patient that it may take 6 months to see an effect
  • Elicit whether the adolescent is troubled by symptoms and address psychosocial issues
  • ACOG suggests that in the setting of severe acne, a discussion regarding risk of scarring if acne left untreated should be considered
  • Insufficient evidence currently to advise regarding diet and acne

Learn More – Primary Sources:

ACOG Committee Opinion 789: Screening and Management of the Hyperandrogenic Adolescent

Modified Ferriman–Gallwey scoring chart  

Visually scoring hirsutism

Guidelines of care for the management of acne vulgaris – Journal of the American Academy of Dermatology

iPLEDGE PROGRAM

Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls

Take a post-test and get CME credits

TAKE THE POST TEST

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All Alerts Posts
Next >

Related ObG Topics:

Polycystic Ovary Syndrome: Making the Diagnosis
PCOS: Targeting Treatments to Improve Reproductive Outcomes and Reduce CVD
Practical info for your gynecology practice
Hormonal Contraception Benefits – Beyond Pregnancy Prevention
Just how Common is Nonclassic Congenital Adrenal Hyperplasia?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site